July 02, 2020
1 min read

NYU Langone appoints associate director for clinical research

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Janice M. Mehnert, MD, has been appointed associate director for clinical research at NYU Langone Health’s Perlmutter Cancer Center.

Mehnert, recognized for her expertise in early phase therapeutics and treatment of skin malignancies, previously served as associate professor of medicine at Robert Wood Johnson Medical School and regional phase 1 clinical program director at Rutgers Cancer institute.

Janice M. Mehnert, MD
Janice M. Mehnert

“The science at NYU Langone is just extraordinary, and the translational link between the clinic and the lab at Perlmutter Cancer Center is something I'm really looking forward to helping to grow,” Mehnert said in a press release.

In her new role, she will enhance Perlmutter Cancer Center’s interactions with the NCI-Cancer Therapy Evaluation Program, expand early phase trial activity in conjunction with the cancer center’s network sites in Long Island and Brooklyn, and strive to develop a strong culture of clinical and translational investigation. She also will see patients with the melanoma/skin and phase 1 disease management groups.

“We are thrilled to attract an individual as talented and accomplished as Janice Mehnert to oversee clinical research across our large network,” Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center, said in the release. “We look forward to having her take our rapidly expanding clinical trial efforts to new heights to the benefit of the Perlmutter Cancer Center patient population.”